ID   NRS-1
AC   CVCL_4871
DR   CLO; CLO_0050021
DR   BioSample; SAMN03472176
DR   RCB; RCB1188
DR   Wikidata; Q54931041
RX   PubMed=7599791;
RX   PubMed=23665679;
RX   PubMed=23882450;
CC   Population: Japanese.
CC   Doubling time: 68 hours (Note=At 15th passage), 64 hours (Note=At 25th passage) (PubMed=7599791).
CC   Sequence variation: Gene fusion; HGNC; 3819; FOXO1 + HGNC; 8617; PAX3; Name(s)=PAX3-FOXO1, PAX3-FKHR (PubMed=7599791).
CC   Derived from site: Metastatic; Left calf muscle; UBERON=UBERON_0004256.
ST   Source(s): RCB
ST   Amelogenin: X
ST   CSF1PO: 12,13
ST   D13S317: 8,11
ST   D16S539: 9,10
ST   D5S818: 11,12
ST   D7S820: 8
ST   TH01: 9
ST   TPOX: 9,11
ST   vWA: 18,20
DI   NCIt; C3749; Alveolar rhabdomyosarcoma
DI   ORDO; Orphanet_99756; Alveolar rhabdomyosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   7Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 29-06-23; Version: 17
//
RX   PubMed=7599791; DOI=10.1007/BF00191348;
RA   Ogose A., Motoyama T., Hotta T., Watanabe H.;
RT   "In vitro differentiation and proliferation in a newly established
RT   human rhabdomyosarcoma cell line.";
RL   Virchows Arch. 426:385-391(1995).
//
RX   PubMed=23665679; DOI=10.1038/onc.2013.129;
RA   Sokolowski E., Turina C.B., Kikuchi K., Langenau D.M., Keller C.;
RT   "Proof-of-concept rare cancers in drug development: the case for
RT   rhabdomyosarcoma.";
RL   Oncogene 33:1877-1889(2014).
//
RX   PubMed=23882450; DOI=10.3389/fonc.2013.00183;
RA   Hinson A.R.P., Jones R., Crose L.E.S., Belyea B.C., Barr F.G.,
RA   Linardic C.M.;
RT   "Human rhabdomyosarcoma cell lines for rhabdomyosarcoma research:
RT   utility and pitfalls.";
RL   Front. Oncol. 3:183.1-183.12(2013).
//